Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Peter Canellos, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U10CA032291 (BURSTEIN, HAROLD J.) Apr 1, 1982 - Mar 31, 2015
    Cancer and Leukemia Group B
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Canellos GP, LaCasce AS. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 04 19; 378(16):1560. PMID: 29671468.
    Citations:    Fields:    Translation:Humans
  2. DeVita VT, Canellos GP. Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna. Tumori. 2016 Mar-Apr; 102(2):124-6. PMID: 27002947.
    Citations: 1     Fields:    Translation:Humans
  3. Canellos G, Devita V. Gianni Bonadonna (1934-2015). Leuk Lymphoma. 2016; 57(4):739. PMID: 26752549.
    Citations:    Fields:    Translation:Humans
  4. Canellos G, DeVita V. Gianni Bonadonna: A Personal Remembrance. Oncologist. 2015 Nov; 20(11):1348-9. PMID: 26854300.
    Citations:    Fields:    Translation:Humans
  5. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
    Citations: 39     Fields:    Translation:Humans
  6. Canellos GP. Advanced DLBCL: as systemic therapy improves, the need for RT diminishes. Oncology (Williston Park). 2014 Dec; 28(12):1085-6. PMID: 25510807.
    Citations:    Fields:    Translation:Humans
  7. Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014 Jan 20; 32(3):163-8. PMID: 24441526.
    Citations: 45     Fields:    Translation:Humans
  8. Canellos GP. Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited. Oncology (Williston Park). 2012 Dec; 26(12):1199-200, 1202. PMID: 23413601.
    Citations:    Fields:    Translation:Humans
  9. Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50. PMID: 22421007.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  10. Canellos GP. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol. 2012 Jun 20; 30(18):2171-2. PMID: 22547611.
    Citations: 5     Fields:    Translation:Humans
  11. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65. PMID: 22133772.
    Citations: 54     Fields:    Translation:HumansCTClinical Trials
  12. Cote GM, Canellos GP. Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep. 2011 Sep; 6(3):180-6. PMID: 21503634.
    Citations: 1     Fields:    Translation:Humans
  13. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20. PMID: 21355087.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  14. DeVita VT, Canellos GP. Hematology in 2010: New therapies and standard of care in oncology. Nat Rev Clin Oncol. 2011 Feb; 8(2):67-8. PMID: 21278770.
    Citations: 4     Fields:    Translation:Humans
  15. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011 Apr; 22(4):910-915. PMID: 20952598.
    Citations: 27     Fields:    Translation:Humans
  16. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010 Mar 20; 28(9):1611-5. PMID: 20159818.
    Citations: 16     Fields:    Translation:Humans
  17. Canellos GP. Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option? Oncologist. 2009 Dec; 14(12):1167-8. PMID: 20008306.
    Citations: 1     Fields:    Translation:Humans
  18. Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10; 361(24):2390-1. PMID: 20007568.
    Citations: 7     Fields:    Translation:Humans
  19. Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol. 2010 Jan 01; 28(1):e8. PMID: 19933898.
    Citations: 5     Fields:    Translation:HumansCells
  20. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8. PMID: 19917845.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  21. Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct; 50(10):1606-17. PMID: 19626540.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  22. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74. PMID: 19001324.
    Citations: 48     Fields:    Translation:Humans
  23. Canellos GP. What constitutes "improved prognosis"? J Clin Oncol. 2008 Apr 20; 26(12):1913-4. PMID: 18421041.
    Citations: 1     Fields:    Translation:Humans
  24. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. PMID: 18342784.
    Citations: 43     Fields:    Translation:Humans
  25. Canellos GP. Relapsed and refractory Hodgkin's lymphoma: new avenues? Hematol Oncol Clin North Am. 2007 Oct; 21(5):929-41. PMID: 17908629.
    Citations: 1     Fields:    Translation:Humans
  26. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007 Jul; 48(7):1313-9. PMID: 17613759.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  27. Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP. High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007 May; 48(5):870-80. PMID: 17487729.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  28. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9. PMID: 17426059.
    Citations: 77     Fields:    Translation:HumansCTClinical Trials
  29. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103. PMID: 17325852.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  30. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006 Aug; 47(8):1511-7. PMID: 16966261.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  31. Krueger G, Canellos G. Where does hematology end and oncology begin? Questions of professional boundaries and medical authority. J Clin Oncol. 2006 Jun 01; 24(16):2583-8. PMID: 16735712.
    Citations:    Fields:    Translation:Humans
  32. Cheson BD, Canellos GP. The cancer and leukemia group B lymphoma committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3572s-5s. PMID: 16740787.
    Citations: 1     Fields:    Translation:Humans
  33. Canellos GP. Introduction to a special series of unique entities within the spectrum of large-cell lymphoma. Oncologist. 2006 Apr; 11(4):374. PMID: 16614232.
    Citations:    Fields:    Translation:Humans
  34. Canellos GP. Clinical trials in North America. Eur J Haematol Suppl. 2005 Jul; (66):121-4. PMID: 16007880.
    Citations:    Fields:    Translation:Humans
  35. Wilson WH, Porcu P, Hurd D, Martin SE, Czuczman M, Niedzwiecki D, Saint Louis JD, Johnson JL, Cheson B, Canellos GP, Zelenetz AD. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. J Clin Oncol. 2005 Jun; 23(16_suppl):6530. PMID: 27943874.
  36. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol. 2005 Jul 20; 23(21):4574-6. PMID: 15837972.
    Citations: 10     Fields:    Translation:Humans
  37. Canellos GP. Lymphoma: present and future challenges. Semin Hematol. 2004 Oct; 41(4 Suppl 7):26-31. PMID: 15768476.
    Citations: 3     Fields:    Translation:Humans
  38. Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004 Apr 15; 22(8):1532-3. PMID: 15084636.
    Citations: 7     Fields:    Translation:Humans
  39. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48. PMID: 15042678.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  40. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92. PMID: 15061202.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  41. Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003 Sep 01; 98(5):978-82. PMID: 12942565.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  42. Canellos G. Prognostic factors in large-cell lymphoma. Clin Adv Hematol Oncol. 2003 May; 1(5):269-70. PMID: 16224419.
    Citations:    Fields:    Translation:Humans
  43. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15; 21(4):607-14. PMID: 12586796.
    Citations: 89     Fields:    Translation:HumansCTClinical Trials
  44. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol. 2003 Feb; 14(2):268-72. PMID: 12562654.
    Citations: 5     Fields:    Translation:Humans
  45. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 02; 346(18):1417-8. PMID: 11986425.
    Citations: 23     Fields:    Translation:Humans
  46. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002 Apr 15; 20(8):2101-8. PMID: 11956271.
    Citations: 76     Fields:    Translation:Humans
  47. Canellos GP. New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. J Clin Oncol. 2002 Feb 01; 20(3):607-9. PMID: 11821436.
    Citations:    Fields:    Translation:Humans
  48. Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1:112-6. PMID: 12078891.
    Citations: 4     Fields:    Translation:Humans
  49. Johnson EA, Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92. PMID: 12197224.